Snapshot from Jul 29, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / ANI Pharma CFO stock sales
Business insider trading

ANI Pharma CFO stock sales

Analysis based on 6 articles · First reported Jul 09, 2026 · Last updated Jul 13, 2026

Sentiment
0
Attention
1
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The insider sales are routine and unlikely to materially affect ANI Pharmaceuticals' stock price. The company's strong operational performance and raised guidance support a positive outlook.

pharmaceuticals
Event Summary

Stephen P. Carey, SVP & CFO of ANI Pharmaceuticals, sold shares of common stock on June 29 and July 2, 2026, under a Rule 10b5-1 trading plan adopted on March 6, 2026. The sales were modest relative to his holdings, representing 1.6% and 2% of his direct shares, respectively. The transactions were pre-scheduled and not indicative of a change in outlook. ANI Pharmaceuticals reported strong Q1 results with revenue up 20.5% to $237.5 million, driven by Cortrophin Gel growth, and raised full-year guidance. The board authorized a $100 million buyback in May.

Key Actions
70 ANI Pharmaceuticals raised guidance
50 ANI Pharmaceuticals authorized buyback
10 Stephen P. Carey sold shares
Entities Involved
stock
ANI Pharmaceuticals
ANI Pharmaceuticals is the company whose CFO sold shares; it reported strong Q1 results and raised guidance, indicating positive business momentum.
Importance 100.0 Sentiment 60.0
per
Stephen P. Carey
Stephen P. Carey, SVP & CFO, sold shares under a pre-arranged plan; the sales were modest and not a signal of negative outlook.
Importance 80.0 Sentiment 0.0
per
Nikhil Lalwani
Nikhil Lalwani is CEO of ANI Pharmaceuticals; he commented on solid Q1 performance but was not directly involved in the stock sales.
Importance 30.0 Sentiment 50.0
exch
Nasdaq
Nasdaq is the exchange where ANI Pharmaceuticals is listed; the event has no direct impact on Nasdaq.
Importance 10.0 Sentiment 0.0
index
S&P 500
S&P 500 is a benchmark index; ANI Pharmaceuticals' stock has outperformed it, but the event is not material to the index.
Importance 5.0 Sentiment 0.0
cnt
United States
United States is the primary market for ANI Pharmaceuticals; the event has no direct impact on the country.
Importance 5.0 Sentiment 0.0
Relationships
Nasdaq related ↔ S&P 500
Nasdaq related ↔ United States
S&P 500 related ↔ United States
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.